Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Re-ACT Study: Prognostic Evaluation and Systematic Re-Assessment of Chol- Angiocarcinoma Therapy

NCT07814586 is registered in ClinicalTrials.gov with Karolinska University Hospital as lead sponsor.

NCT NCT07814586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07814586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Re-ACT Study: Prognostic Evaluation and Systematic Re-Assessment of Chol- Angiocarcinoma Therapy
Lead sponsor
Karolinska University Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2031
Enrollment
900 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma